ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,942Medicare Part D Prescriptions Filled, Including Refills

Rank: 64 out of 393

$496K Total Retail Price of All Prescriptions

Rank: 64 out of 393

516 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
24% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nevada
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 516 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

17% of this provider’s 516 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 7,728 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nevada
AMLODIPINE BESYLATE 452 422 1 4
LEVOTHYROXINE SODIUM 415 342 2 3
HYDROCODONE-ACETAMINOPHEN 320 267 S3 3 5
ZOLPIDEM TARTRATE 300 257 4 11
SIMVASTATIN 279 230 5 1
LISINOPRIL 274 225 6 2
OMEPRAZOLE 252 232 7 6
LOVASTATIN 241 213 8 14
ATENOLOL 205 196 9 13
METFORMIN HCL 187 116 10 7
FLUOXETINE HCL 179 179 11 37
SPIRONOLACTONE 176 166 12 82
FUROSEMIDE 142 134 13 8
GABAPENTIN 141 128 14 15
BENAZEPRIL HCL 136 112 15 40
HYDROCHLOROTHIAZIDE 132 128 16 10
LOSARTAN POTASSIUM 129 124 17 12
PAROXETINE HCL 123 95 18 61
ALENDRONATE SODIUM 100 97 19 16
METOPROLOL TARTRATE 94 75 20 9
DIOVAN 90 86 21 69
GLIMEPIRIDE 88 70 22 39
ATORVASTATIN CALCIUM 86 60 23 19
WARFARIN SODIUM 86 77 23 17
METOPROLOL SUCCINATE 84 79 25 22
FLUTICASONE PROPIONATE 84 69 25 27
ALLOPURINOL 84 82 25 26
LISINOPRIL-HYDROCHLOROTHIAZIDE 79 73 28 24
PRAVASTATIN SODIUM 78 78 29 18
LEVOXYL 77 77 30 120
DIGOXIN 75 75 31 66
AMITRIPTYLINE HCL 68 46 R 32 72
SERTRALINE HCL 65 55 33 28
POTASSIUM CHLORIDE 61 59 34 20
OXYBUTYNIN CHLORIDE 61 61 34 90
PREDNISONE 60 57 36 65
PROAIR HFA 60 36 36 68
SYNTHROID 59 53 38 44
CITALOPRAM HBR 57 33 39 23
ESTRADIOL 57 52 R 39 93
BENAZEPRIL-HYDROCHLOROTHIAZIDE 56 56 41 179
DONEPEZIL HCL 54 54 42 34
NEXIUM 53 39 43 84
METFORMIN HCL ER 50 50 44 63
VERAPAMIL ER 50 41 44 86
ADVAIR DISKUS 50 38 44 53
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 3, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.